All In Biotech

Drug Trial Radar · NCT04578834

Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients

A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase III Study to Evaluate the Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients

Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 517 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

517

Actual

Start

Jan 25, 2021

Primary completion

Sep 19, 2025

Study completion Sep 19, 2025

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Oct 8, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study was designed as a multicenter, randomized, double-blind, placebo controlled study to demonstrate the superiority of iptacopan (LNP023) at a dose of 200 mg b.i.d. compared to placebo on top of maximally tolerated ACEi or ARB on reduction of proteinuria and slowing renal disease progression in primary IgA Nephropathy patients.

Conditions

  • IgA Nephropathy

Interventions

  • PlaceboDrug

    Placebo to LNP023 200mg b.i.d

  • LNP023Drug

    LNP023 200mg b.i.d

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Ratio to Baseline in UPCR at 9 Months - Interim AnalysisTime frame: Baseline and 9 months
  2. Annualized Total eGFR Slope Estimated Over 24 Months - Final AnalysisTime frame: 24 months

Locations

177 sites in 35 countries. Site status is shown where the registry gives one.

  • AZ Kidney Dise and Hypertension Ctr

    Glendale, Arizona

  • AKDHC Medical Research ServicesLLC

    Phoenix, Arizona

  • UCLA Medical Center

    Los Angeles, California

  • Kaiser Permanente

    San Diego, California

  • North America Research Institute

    San Dimas, California

  • University of Colorado Anschutz

    Aurora, Colorado

  • Nephrology Associates PA

    Newark, Delaware

  • Boise Kidney and Hypertension

    Boise, Idaho

  • CaRe Research

    Chubbuck, Idaho

  • Nep Assoc of Northern Illinois

    Hinsdale, Illinois

  • Renal Associates of Baton Rouge

    Baton Rouge, Louisiana

  • Johns Hopkins Hospital

    Baltimore, Maryland

  • Brigham and Womens Hosp Harvard Med School

    Boston, Massachusetts

  • University of Michigan

    Ann Arbor, Michigan

  • Mayo Clinic Rochester

    Rochester, Minnesota

  • Clin Rsrch Consult a JCCT Company

    Kansas City, Missouri

  • DaVita Clinical Research

    Las Vegas, Nevada

  • New Jersey Kidney Care

    Jersey City, New Jersey

  • Columbia University Irving Medical

    New York, New York

  • Dallas Renal Group

    Dallas, Texas

  • Prolato Clinical Research Center

    Houston, Texas

  • Univ of Washington Medi Cen

    Seattle, Washington

  • Novartis Investigative Site

    CABA, Argentina

  • Novartis Investigative Site

    CABA, Argentina

  • Novartis Investigative Site

    Santa Fe, Argentina

  • Novartis Investigative Site

    Córdoba, Córdoba Province, Argentina

  • Novartis Investigative Site

    Córdoba, Córdoba Province, Argentina

  • Novartis Investigative Site

    Westmead, New South Wales, Australia

  • Novartis Investigative Site

    Woolloongabba, Queensland, Australia

  • Novartis Investigative Site

    Adelaide, South Australia, Australia

  • Novartis Investigative Site

    Parkville, Victoria, Australia

  • Novartis Investigative Site

    St Albans, Victoria, Australia

  • Novartis Investigative Site

    Edegem, Belgium

  • Novartis Investigative Site

    Leuven, Belgium

  • Novartis Investigative Site

    Roeselare, West Vlaanderen, Belgium

  • Novartis Investigative Site

    Belo Horizonte, Minas Gerais, Brazil

  • Novartis Investigative Site

    Curitiba, Paraná, Brazil

  • Novartis Investigative Site

    Porto Alegre, Rio Grande do Sul, Brazil

  • Novartis Investigative Site

    São José do Rio Preto, São Paulo, Brazil

  • Novartis Investigative Site

    São Paulo, São Paulo, Brazil

Showing 40 of 177 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.